SCHEMBL16201368

SCHEMBL16201368

CCCN(C)Cc1c[nH]nc1-c1cccc(C(C)=O)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CARM1 Q86X55 3/20 0.38
PRMT6 Q96LA8 3/20 0.38
PRMT1 Q99873 3/20 0.38
PRMT8 Q9NR22 3/20 0.38
MAPK8 P45983 2/20 0.38
KDR P35968 2/20 0.38
PRMT3 O60678 2/20 0.38
MAP4K4 O95819 2/20 0.38
CSNK1G2 P78368 2/20 0.38
CLK4 Q9HAZ1 2/20 0.38
MKNK2 Q9HBH9 2/20 0.38
MAP4K5 Q9Y4K4 2/20 0.38
PLK4 O00444 1/20 0.38
DCLK1 O15075 1/20 0.38
ROCK2 O75116 1/20 0.38
PRKD3 O94806 1/20 0.38
PAK4 O96013 1/20 0.38
CHEK2 O96017 1/20 0.38
INSR P06213 1/20 0.38
CDK1 P06493 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16201202 0.90 PRMT1 (0.46) CARM1PRMT6PRMT1PRMT8MAPK8
SCHEMBL16201434 0.88 HSD17B1 (0.39) CARM1PRMT6PRMT1PRMT8MAPK8
SCHEMBL19413170 0.88 PRMT1 (0.48) CARM1PRMT6PRMT1PRMT8MAPK8
SCHEMBL16201440 0.87 CDK8 (0.46) MAPK8ROCK2CSNK1DCDK8ROCK1
SCHEMBL16201382 0.82 SMN1; SMN2 (0.41) CARM1PRMT6PRMT1PRMT8PRMT3
SCHEMBL16201410 0.81 NOTUM (0.38) CARM1PRMT6PRMT1PRMT8PRMT3
SCHEMBL16201373 0.81 STK4 (0.44) CARM1PRMT6PRMT1PRMT8STK3
SCHEMBL16201329 0.81 NPC1 (0.44) CARM1PRMT6PRMT1PRMT8PRMT3
SCHEMBL16201341 0.80 MOK (0.37) CARM1PRMT6PRMT1PRMT8PRMT3
SCHEMBL16201387 0.80 GAA (0.41) CLK4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9776972-B2 Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof EPIZYME INC. (US) 2017-10-03 US disclosed
US-9346761-B2 Arginine methyltransferase inhibitors and uses thereof Epizyme, Inc. (US) 2016-05-24 US disclosed
US-20160137609-A1 PYRAZOLE DERIVATIVES AS ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2016-05-19 US disclosed
US-20140323537-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2014-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140323537-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF PRMT1, PRMT3, PRMT5 CARM1 11/4885PRMT6 4/4885PRMT1 1/4885
US-20160137609-A1 PYRAZOLE DERIVATIVES AS ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF PRMT1, PRMT3, PRMT5 CARM1 12/4885PRMT6 5/4885PRMT1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.